ClinicalTrials.Veeva

Menu
Houston Research Institute | Houston, TX logo

Houston Research Institute | Houston, TX

Research site
About
Houston Research Institute is dedicated to conducting clinical trials in the areas of Hepatology and Gastroenterology, with a special focus on fatty liver disease. We pride ourselves on conducting high quality research as a complement to the medical care that our volunteers receive from their routine care center.

Site insights

Top conditions

Top treatments

Survodutide
LY3298176
Semaglutide
TERN-501
HU6
K-808
MK-6024
Lanifibranor
Resmetirom
Pemafibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Kira Harris

Verified by this site

Active trials

14 of 15 total trials

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Rese...

Active, not recruiting
Nonalcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
Drug: Semaglutide
Drug: Placebo

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic ste...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Drug: Placebo
Drug: Efimosfermin
Locations recently updated

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study wi...

Enrolling
Obesity
Drug: Retatrutide
Drug: Tirzepatide

A Trial to Investigate the Pharmacokinetics (PK) Effects and Safety Profile of K-808 (Pemafibrate) in Primary Biliary Cholangitis (PBC) Subjects with...

Enrolling
Compensated Cirrhosis
Primary Biliary Cholangitis
Drug: K-808

This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of...

Not yet enrolling
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Compensated Liver Cirrhosis
Drug: BI 770371
Drug: Placebo for BI 770371

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction fro...

Active, not recruiting
Nonalcoholic Fatty Liver Disease
Metabolic Dysfunction-Associated Steatotic Liver Disease
Drug: Efinopegdutide
Locations recently updated

The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic live...

Enrolling
Alcohol-related Liver Disease
Drug: Cagrilintide
Drug: NNC0194-0499 placebo

This study is open to adults who are at least 18 years old and have:* a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Liver Fibrosis
Drug: Survodutide
Drug: Placebo

This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepat...

Active, not recruiting
Fatty Liver
Nonalcoholic Steatohepatitis
Drug: HU6
Other: Placebo
Locations recently updated

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Active, not recruiting
Non-alcoholic Steatohepatitis
Drug: Placebo
Drug: Semaglutide

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: Cilofexor (CILO)/Firsocostat (FIR)
Drug: PTM SEMA

Trial sponsors

Boehringer Ingelheim logo
Merck Sharp & Dohme (MSD) logo
Novo Nordisk logo
Boston Scientific logo
Gilead Sciences logo
I
Kowa logo
Lilly logo
Madrigal Pharmaceuticals logo
Rivus Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems